Next Article in Journal
Could Protons and Carbon Ions Be the Silver Bullets Against Pancreatic Cancer?
Next Article in Special Issue
A Splice Intervention Therapy for Autosomal Recessive Juvenile Parkinson’s Disease Arising from Parkin Mutations
Previous Article in Journal
Absolute Binding Free Energy Calculations for Highly Flexible Protein MDM2 and Its Inhibitors
Previous Article in Special Issue
Altered Cerebral Blood Flow and Potential Neuroprotective Effect of Human Relaxin-2 (Serelaxin) During Hypoxia or Severe Hypovolemia in a Sheep Model
Review

Caffeine: An Overview of Its Beneficial Effects in Experimental Models and Clinical Trials of Parkinson’s Disease

IRCCS Centro Neurolesi “Bonino-Pulejo”, Via Provinciale Palermo, Contrada Casazza, 98124 Messina, Italy
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(13), 4766; https://doi.org/10.3390/ijms21134766
Received: 30 May 2020 / Revised: 30 June 2020 / Accepted: 3 July 2020 / Published: 4 July 2020
(This article belongs to the Collection Neuroprotective Strategies)
Parkinson’s Disease (PD) is a neurological disease characterized by the progressive degeneration of the nigrostriatal dopaminergic pathway with consequent loss of neurons in the substantia nigra pars compacta and dopamine depletion. The cytoplasmic inclusions of α-synuclein (α-Syn), known as Lewy bodies, are the cytologic hallmark of PD. The presence of α-Syn aggregates causes mitochondrial degeneration, responsible for the increase in oxidative stress and consequent neurodegeneration. PD is a progressive disease that shows a complicated pathogenesis. The current therapies are used to alleviate the symptoms of the disease without changing its clinical course. Recently, phytocompounds with neuroprotective effects and antioxidant properties such as caffeine have aroused the interest of researchers. The purpose of this review is to summarize the preclinical studies present in the literature and clinical trials recorded in ClinicalTrial.gov, aimed at illustrating the effects of caffeine used as a nutraceutical compound combined with the current PD therapies. Therefore, the preventive effects of caffeine in the neurodegeneration of dopaminergic neurons encourage the use of this alkaloid as a supplement to reduce the progress of the PD. View Full-Text
Keywords: caffeine; Parkinson’s Disease; experimental models; neuroprotective effects; clinical trials caffeine; Parkinson’s Disease; experimental models; neuroprotective effects; clinical trials
Show Figures

Graphical abstract

MDPI and ACS Style

Schepici, G.; Silvestro, S.; Bramanti, P.; Mazzon, E. Caffeine: An Overview of Its Beneficial Effects in Experimental Models and Clinical Trials of Parkinson’s Disease. Int. J. Mol. Sci. 2020, 21, 4766. https://doi.org/10.3390/ijms21134766

AMA Style

Schepici G, Silvestro S, Bramanti P, Mazzon E. Caffeine: An Overview of Its Beneficial Effects in Experimental Models and Clinical Trials of Parkinson’s Disease. International Journal of Molecular Sciences. 2020; 21(13):4766. https://doi.org/10.3390/ijms21134766

Chicago/Turabian Style

Schepici, Giovanni, Serena Silvestro, Placido Bramanti, and Emanuela Mazzon. 2020. "Caffeine: An Overview of Its Beneficial Effects in Experimental Models and Clinical Trials of Parkinson’s Disease" International Journal of Molecular Sciences 21, no. 13: 4766. https://doi.org/10.3390/ijms21134766

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop